Cassava Sciences, Inc. (FRA:PX91)

Germany flag Germany · Delayed Price · Currency is EUR
1.814
+0.041 (2.34%)
At close: Feb 20, 2026
Market Cap87.34M -22.5%
Revenue (ttm)n/a
Net Income-90.37M
EPS-1.87
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume53
Open1.814
Previous Close1.772
Day's Range1.814 - 1.814
52-Week Range1.030 - 3.902
Betan/a
RSI52.59
Earnings DateMar 3, 2026

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Te... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 30
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PX91
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements